ArticleTransboundary and emerging diseases2026
miR-375 Regulates Extracellular Vesicle Secretion From Giardia duodenalis via Targeting Rab1a.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- miR-375 Regulates Extracellular Vesicle Secretion From Giardia duodenalis via Targeting Rab1a.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Giardia duodenalis (G. duodenalis) represents a prevalent zoonotic protozoan pathogen responsible for diarrheal disorders across human and animal hosts. To date, no licensed effective vaccines have been developed against giardiasis, and the emergence of drug resistance progressively impairs the efficacy of conventional clinical chemotherapy. Extracellular vesicles (EVs) derived from G. duodenalis (GEVs) exert pivotal functions in mediating parasite immune evasion as well as the initiation of host inflammatory cascades; nevertheless, the molecular regulatory circuits underlying GEV biosynthesis and secretion remain poorly defined. Previous bioinformatic predictions implicate Rab1a in vesicular trafficking within G. duodenalis, whereas its concrete biological contribution to GEV secretion has not been experimentally validated. The present work was designed to screen microRNAs (miRNAs) targeting Rab1a and further elucidate their modulatory effects on GEVs biogenesis. GEVs were purified from G. duodenalis WB-strain trophozoites, and their identity was verified via transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA, modal diameter: 164.7 nm), plus Western blot detection of classic extracellular vesicle biomarker proteins. High-throughput miRNA sequencing was subsequently conducted to filter candidate miRNAs capable of interacting with the Rab1a 3' untranslated region (3'UTR), from which miR-375, miR-133, and miR-999 were shortlisted as prospective regulatory molecules. Functional verification revealed that only miR-375 robustly repressed Rab1a expression at both mRNA and protein abundances. Dual-luciferase reporter assays further authenticated the direct physical interaction between miR-375 and the Rab1a 3'UTR. Consistently, ectopic overexpression of miR-375 resulted in a prominent decline in cellular GEV secretion. In summary, our experimental data corroborate that endogenous G. duodenalis miR-375 suppresses Rab1a expression at the post-transcriptional level to constrain downstream GEV release. The newly characterized miR-375-Rab1a-GEVs regulatory axis deepens our mechanistic understanding of post-transcriptional modulation governing vesicle formation in G. duodenalis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.